Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:1090-1096
Published online before print April 3, 2008, doi: 10.1161/ATVBAHA.108.165423
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
28/6/1090    most recent
ATVBAHA.108.165423v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Braunersreuther, V.
Right arrow Articles by Mach, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Braunersreuther, V.
Right arrow Articles by Mach, F.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Hazardous Substances DB
*HEPARIN
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:1090.)
© 2008 American Heart Association, Inc.


Integrative Physiology/Experimental Medicine

A Novel RANTES Antagonist Prevents Progression of Established Atherosclerotic Lesions in Mice

Vincent Braunersreuther; Sabine Steffens; Claire Arnaud; Graziano Pelli; Fabienne Burger; Amanda Proudfoot; François Mach

From the Division of Cardiology, Department of Medicine (V.B., S.S., C.A., G.P., F.B., F.M.), University Hospital, Foundation for Medical Researches, Geneva, Switzerland; and Geneva Research Centre Merck Serono International S.A., Geneva, Switzerland (A.P.).

Correspondence to François Mach, Division of Cardiology, Department of Medicine, University Hospital, Foundation for Medical Researches, 64 Avenue Roseraie, 1211 Geneva, Switzerland. E-mail Francois.Mach{at}medecine.unige.ch

Background— Atherosclerosis is a chronic inflammatory disease that represents the primary cause of death through coronary disease and stroke. Chemokines are known to play a crucial role in this disease by recruiting inflammatory leukocytes to the endothelium. Recently, the chemokine variant [44AANA47]-RANTES was shown to impair inflammatory cell recruitment in vivo by interfering with heparin binding and oligomerization.

Methods and Results— In this study we report that curative treatment with [44AANA47]-RANTES limits atherosclerotic plaque formation in LDLr–/– mice. This was associated with reduced infiltration of T cells and macrophages and reduced production of matrix metalloproteinase (MMP)-9. By contrast, the relative smooth muscle cell and collagen content was increased, indicating a more stable plaque phenotype. In addition, we provide evidence for direct inhibition of leukocyte recruitment into aortic root lesions, attenuated leukocyte rolling and arrest in mesenteric vessels, as well as a reduced proinflammatory response following Con A stimulation in vitro.

Conclusions— Interference with chemokine oligomerization and chemokine/heparin interactions is a powerful novel approach that inhibits progression of established atherosclerosis in mice. By inhibiting leukocyte recruitment into plaques, [44AANA47]-RANTES mediates a less inflammatory plaque phenotype and thus reduced systemic inflammatory state.


Key Words: atherosclerosis • inflammation • leukocytes • chemokines




This article has been cited by other articles:


Home page
J. Leukoc. Biol.Home page
J. M. van Gils, J. J. Zwaginga, and P. L. Hordijk
Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases
J. Leukoc. Biol., February 1, 2009; 85(2): 195 - 204.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
Y. S. Bae, J. H. Lee, S. H. Choi, S. Kim, F. Almazan, J. L. Witztum, and Y. I. Miller
Macrophages Generate Reactive Oxygen Species in Response to Minimally Oxidized Low-Density Lipoprotein: Toll-Like Receptor 4- and Spleen Tyrosine Kinase-Dependent Activation of NADPH Oxidase 2
Circ. Res., January 30, 2009; 104(2): 210 - 218.
[Abstract] [Full Text] [PDF]